How Does Novavax Stack Up Against Today's Vaccine Leaders?
Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) have remained a step ahead of most potential coronavirus vaccine rivals. That's thanks to their products' overall efficacy of more than 90%. But one up-and-coming vaccine maker just reported data that may give these leaders a run for their money.
Novavax (NASDAQ: NVAX) plans to submit its coronavirus vaccine candidate for emergency authorization in various countries including the U.S. in the third quarter. And the company has already lined up orders for doses worldwide.
Now the question is whether Novavax has what it takes to join leaders Pfizer and Moderna at the top. Let's take a look at how Novavax compares to its more advanced rivals.
Source Fool.com
